INTRODUCTION

Normal and malignant hematopoiesis
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Division of Pediatric Oncology, Johns Hopkins University, Baltimore, MD, USA Oncogene (2007) 26, 6686; doi:10.1038/sj.onc.1210753 Hematopoiesis has served as a paradigm for investigation of normal mammalian developmental processes over the last four decades. Rapid turnover of mature blood elements requires their ongoing replacement from the bone marrow throughout adult life. The accessibility of marrow stem and progenitor cells facilitated the elucidation of the cellular basis of hematopoiesis, and the ability to grow hematopoietic colonies enabled isolation of cytokines that drive the proliferation and differentiation of specific marrow progenitors. When investigation of lineage-specific transcription began approximately two decades ago, the clinical importance of hemoglobin and antibodies inspired early characterization of the b-globin and immunoglobulin genes.
The clinical importance of hematopoiesis has also inspired its widespread study. In addition to benign hematologic and marrow failure syndromes, leukemias, lymphomas and myelodysplastic syndromes arise from hematopoietic cells, and hematopoietic stem cells serve as a source for marrow transplantation for malignant and non-malignant conditions. Moreover, many chemotherapy agents markedly reduce blood counts, and cytokines that stimulate the proliferation of specific lineages have already become part of clinical practice.
While many of the important regulators of normal hematopoiesis have been identified, much work remains to understand how these integrate to allow progressive commitment from the pluripotent hematopoietic stem cell to the individual lineages and to provide responsiveness to environmental cues. The recent recognition of the importance of non-translated RNAs provides another layer of control that remains to be explored in depth. In addition, progress in understanding the nature of stem cells, those cells that have the capacity to both continually reproduce themselves and to give rise to more committed progeny, holds the promise of expanding human hematopoietic stem cells and their progeny, from adult or embryonic sources, to benefit patients with reduced blood counts. Such cells will also likely serve as the ideal vehicle for gene therapy applications meant to correct genetic deficiencies.
The frequent presence of chromosomal translocations in hematologic malignancies provided an early inroad into the transformation process. Many of the genes cloned from the breakpoints of these genetic abnormalities were found to be transcription factors or signaling molecules. The concept that leukemia/lymphoma formation requires disruption of normal transcriptional control of differentiation combined with aberrant signals that increase proliferation and inhibit apoptosis has become widely accepted.
The series of Oncogene reviews presented in this issue focuses on the control of normal hematopoiesis by transcription factors and cytokines in early stem cells and in the myeloid, erythroid, megakaryocyte and lymphoid lineages and, in companion articles, on how these processes are disrupted in myelodysplasias, leukemias or lymphomas that arise from each lineage. Undoubtedly, alterations in several additional processes contribute to transformation, including alterations in cell cycle control, DNA repair and senescence pathways. Applications of global genomic and epigenetic methodologies will likely elucidate multiple changes that differ to some extent between each patient's leukemic blasts. One challenge of modern oncology research is to identify those genetic changes or pathways that contribute to the transformed phenotype and to develop reagents that reverse these processes. Important progress has already been made targeting kinase domains of aberrant signaling proteins, and small molecules that disrupt interaction of mutant transcription factors with cooperating proteins will hopefully also contribute to therapy in the future. 
